GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Gross-Profit-to-Asset %

Oryzon Genomics (STU:ORN) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Oryzon Genomics's annualized Gross Profit for the quarter that ended in Mar. 2024 was €0.00 Mil. Oryzon Genomics's average Total Assets over the quarter that ended in Mar. 2024 was €107.72 Mil. Therefore, Oryzon Genomics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.


Oryzon Genomics Gross-Profit-to-Asset % Historical Data

The historical data trend for Oryzon Genomics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Gross-Profit-to-Asset % Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.36 10.34 10.37 15.38 13.25

Oryzon Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.14 12.85 12.36 14.07 -

Competitive Comparison of Oryzon Genomics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Oryzon Genomics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Gross-Profit-to-Asset % falls into.



Oryzon Genomics Gross-Profit-to-Asset % Calculation

Oryzon Genomics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=14.138/( (104.979+108.359)/ 2 )
=14.138/106.669
=13.25 %

Oryzon Genomics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (108.359+107.089)/ 2 )
=0/107.724
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Oryzon Genomics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oryzon Genomics (STU:ORN) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.